Director Douglas Roeder adds 22,686 shares while stock trades down 63% from 52-week high; repeat buyer at declining prices in loss-making medical device company.
Director Douglas Roeder purchased over 22,600 shares, increasing his stake by nearly one-fifth—his sixth open-market purchase in the last three years. The timing is notable: the stock is trading well below its 52-week high and has declined significantly over the past several months, suggesting he is buying during a sustained pullback rather than at peak levels. Senseonics is not yet profitable and posted a net loss in both the full year and most recent quarter, though the company is growing revenue at a strong rate year-over-year. Roeder has no track record of open-market sales and has consistently added shares on the open market, but all five of his prior purchases at this ticker remain too recent to assess whether they preceded gains or further declines. His repeated buying into a falling stock in a loss-making but growing medical device company could reflect conviction in a longer-term turnaround, but the pattern of purchases at steadily lower prices over several years warrants scrutiny about whether he is averaging down into a deteriorating situation.